Condition: Gastric Cancer · Gastroesophageal Junction Adenocarcinoma · Sponsor: RemeGen Co., Ltd.
The purpose of this study is to evaluate the efficacy and safety of Disitamab Vedotin Combined with Cadonilimab in subjects with HER2-expressing locally advanced or metastatic gastric cancer and gastroesophageal junction adenocarcinoma after progression on first-line therapy.
This description comes directly from the study's public registry record.
Jianmin Fang, Ph.D · +8610-58075763 · Jianminfang@hotmail.com
Always discuss trial participation with your own doctor first.
| Beijing Cancer Hospital | Beijing, Beijing Municipality, China | Recruiting |
| The First Affiliated Hospital of Xiamen University | Xiamen, Fujian, China | Not Yet Recruiting |
| Harbin Medical University Cancer Hospital | Harbin, Heilongjiang, China | Not Yet Recruiting |
| The First Affiliated Hospital of Zhengzhou University | Zhengzhou, Henan, China | Not Yet Recruiting |
| Hubei Cancer Hospital | Wuhan, Hubei, China | Not Yet Recruiting |
| Hunan Cancer Hospital | Changsha, Hunan, China | Recruiting |
| Xuzhou Central Hospital | Xuzhou, Jiangsu, China | Recruiting |
| Shandong Cancer Hospital | Jinan, Shandong, China | Recruiting |
| The Affiliated Hospital of Qingdao University | Qingdao, Shandong, China | Not Yet Recruiting |
| Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine | Shanghai, Shanghai Municipality, China | Not Yet Recruiting |
| West China Hospital of Sichuan University | Chengdu, Sichuan, China | Not Yet Recruiting |
| Yunnan Cancer Hospital | Kunming, Yunnan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06221748